ketamine
Mindfulness, music, visual occlusion in ketamine therapy for depression: do they change outcomes? A qualitative and quantitative analysis of a randomized controlled trial (Kheirkhah, et al, 2025)
"...participants in the combined sensory intervention group reported deeper engagement, a stronger sense of connection to reality, increased focus on the experience..., moments of relief from sadness, and feelings of awe and spiritual insight compared to the control group. "
ketamine
Ketamine Reduces Suicidality-Associated Emergency Department Utilization in Patients With Treatment-Resistant Depression: A 6-Month Mirror-Image Study (Patarroyo-Rodriguez, et al, 2025)
La ketamina reduce la utilización del departamento de emergencias asociada a la suicidabilidad en pacientes con depresión resistente al tratamiento: un estudio de imagen especular de 6 meses
ketamine
Vascular endothelial growth factor: a key factor in the onset and treatment of depression (Wang, et al, 2025)
Factor de crecimiento endotelial vascular: un factor clave en la aparición y tratamiento de la depresión
dmt
Spotlight: N,N-dimethyltryptamine effects on connectome harmonics, subjective experience and comparative psychedelic experiences (Vohryzek, et al, 2025)
"the connectome harmonic repertoire under N,N-dimethyltryptamine (DMT) is reshaped in line with other reported psychedelic compounds - psilocybin, lysergic acid diethylamide (LSD) and ketamine... the repertoire entropy of connectome harmonics increases under DMT, as with those other psychedelics."
ketamine
Spotlight: "Ketamine States: A Journey Through the Mind" (Wolfson, et al, 2025)
Estados de la ketamina: Un viaje a través de la mente
ketamine
Ketamine-assisted psychotherapy, psychedelic methodologies, and the impregnable value of the subjective—a new and evolving approach (Wolfson & Vaid, 2024)
"in a conducive set and settings, these experiences have been demonstrated to be of positive use in psychiatry and psychotherapy, providing a time-out from usual states of mind to facilitate a reshaping of self-experience along with symptomatic relief."
ketamine
Spotlight: Ketamine and psychotherapy for the treatment of psychiatric disorders: systematic review (Kew, et al, 2023)
"...Outcomes were largely positive for the addition of psychotherapy to ketamine treatment...The combination of psychotherapy and ketamine offers promise for the treatment of psychiatric disorders"
ketamine
Spotlight: "Ketamine-Assisted Group Therapy for Work-Related Stress in First Responders and Frontline Health Care Workers" (Flynn, et al, 2025)
"Ketamine is an evidenced-based treatment for depression, and it has shown promise in addressing many other mental health conditions related to work-related stress or burnout, such as anxiety and post-traumatic stress disorder."
ketamine
Spotlight: Ketamine-Occasioned Mystical Experience in Veterans with Treatment-Resistant Depression: A Retrospective Exploratory Analysis (Bhatt, et al, 2025)
Experiencia mística de la ketamina en veteranos con depresión resistente en tratamiento: un análisis exploratorio retrospectivo
ketamine
Spotlight: The Effectiveness of Combining Ketamine and Cognitive Behavioural Therapy in Treating Major Depressive Disorder (2025)
" This study seeks to investigate the combined effectiveness of ketamine and CBT in the treatment of MDD, with the hypothesis that integrated treatment will outperform either modality administered alone."
ketamine
Spotlight: Real-world clinical data on the long-term effectiveness and safety of generic racemic ketamine treatment (Massaneda-Tuneu, et al, 2025)
"...the real-world clinical data presented here suggest a sustained effectiveness and safety profile of longer-term ketamine treatment for up to 6 months for patients with TRD. "
ketamine
Spotlight: "Intravenous Ketamine for Late-Life Treatment-Resistant Depression: A Pilot Study of Tolerability, Safety, Clinical Benefits, and Effect on Cognition (Oughli, et al, 2023)
"This pilot study suggests that repeated IV ketamine infusions are well-tolerated and are associated with improvement in depression and EF in older adults with TRD."
ketamine
Spotlight: From Anesthetic to Neuroprotector: Multi-Omics Reveals Ketamine's Previously Unexplored Neuroprotective Role in Alzheimer's Disease (Gong, et al, 2025)
"This integrative study identifies robust diagnostic biomarkers and nominates ketamine for repurposing in AD. Experimental validation of ketamine's neuroprotective effects and FIBP's role is warranted."
ketamine
Spotlight: Psychedelics and mental health: reimagining care through science, insight, and compassion (Mikellides, et al, 2025)
"These substances are not stand-alone medications; rather, they function as adjuncts to intensive psychotherapeutic processes. Training therapists and establishing ethical, evidence-based protocols is essential."
ketamine
Spotlight: Brain changes associated with depression treatment: a meta-analysis
Meta-analysis of data from 302 depressed subjects yielding 87 foci across 18 experiments examining various depression treatments including pharmacology, psychotherapy, electroconvulsive therapy, psilocybin, and ketamine with brain activity measures in response to emotion tasks in the scanner.
ketamine
Spotlight: NMDA receptor-modulating treatments for cognitive deficits in patients with bipolar disorder: A narrative review (Badrfam, et al, 2025)
"Ketamine infusions have improved processing speed and verbal learning in bipolar disorder patients. Evidence suggests that NMDA receptor-modulating agents play a significant role in improving cognitive function in patients with bipolar disorder. "
ketamine
Spotlight: Nonresponse to Ketamine in Treatment-Resistant Bipolar Depression (Kachlick, et al, 2025)
Ketamine demonstrates a favorable safety and tolerability profile for short time use in TRBD regardless of isolated baseline characteristics, although a more severe comorbidity burden and benzodiazepine use appear to be associated with nonresponse.
fda
Preservative-free formulation of ketamine, NRX-100, Granted FDA Fast-Track Designation for Suicidal Ideation in Patients with Depression, including Bipolar Depression
"Approximately 13 million adults seriously consider suicide each year, 1.5 million attempt suicide, and an American dies from suicide every 11 minutes. NRX-100 – IV ketamine for suicidality in patients with depression, including bipolar depression – designed to help address national crisis."
